Operator

Welcome to the bioMérieux 2025 Third Quarter Sales Conference Call. The call will be structured in 2 parts. First, a presentation by bioMérieux Group management team. [Operator Instructions] I will now hand over to Aymeric Fichet, VP, Investor Relations. Please go ahead.

Aymeric Fichet

Thank you. Good afternoon, good morning, and thank you for joining us to review the Q1 2026 bioMérieux sales performance. I'm online with Pierre Boulud, CEO; together with Guillaume Bouhours, CFO. Please note that this conference call will include forward-looking statements that may change or be modified due to uncertainties and risks related to the company's environment. Accordingly, we cannot give any assurance as to whether we will achieve this objective. I also remind you that today's call is being recorded and that a replay will be available on our website, www.biomerieux-finance.com.

I will now hand the call over to Pierre and Guillaume, and then we will open the call to discussion and questions. Pierre?

Pierre Boulud
Chief Executive Officer

Thank you, Aymeric. Good day to everyone. So let me start with a few general messages before I say a few words about the guidance. We have dealt with a pretty complicated environment in Q1 with a very weak Q1 respiratory epidemiology versus what we already knew was a strong Q1 '25